AGN - Argenica Therapeutics

[System]

Argenica Therapeutics was incorporated on 20 November 2019 as a proprietary Australian company to undertake the development and commercialisation of a novel therapeutic known as ARG-007 developed by world-leading researchers at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). The therapeutic, which is based on arginine rich peptides, has proven neuroprotective properties and therefore can offer protection to the brain following stroke and other acute central nervous system injuries.

The Company's current business is to develop and commercialise ARG-007. Argenica will initially focus on the use of ARG-007 in the treatment of stroke.

The Company has no subsidiaries.

It is anticipated that AGN will list on the ASX during June 2021.

Argenica Therapeutics – Developing Novel Neuroprotective Therapeutics

argenica.com.au

 

[Dona Ferentes]

Contact details	https://argenica.com.au/ +61 8 9329 3396
Principal Activities	Development and commercialisation of a novel therapeutic
GICS industry group	TBA
Issue Price	$0.20
Issue Type	Ordinary Fully Paid Shares
Security code	AGN
Capital to be Raised	$7,000,000
Expected offer close date	21 May 2021
Underwriter	Not underwritten. Alto Capital (Lead Manager)

 

[Dona Ferentes]

AGN listed today. Opened at 31c and held up OK, to close well above IPO at 26c

 

[noirua]

Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer’s treatment​

Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer's treatment

Argenica Therapeutics (ASX:AGN) has reported that pre-clinical data for its flagship ARG-007 product showed the drug inhibited one of the main causes of Alzheimer's Disease.

themarketherald.com.au

Argenica said that in an in-vitro study conducted by Austria-based contract research organisation QPS, ARG-007 was shown to “significantly” inhibit the aggregation of human recombinant Amyloid-Beta (Abeta), which is thought to be one of the main causes of Alzheimer’s.

Live charts: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^AGN&p=0&t=1

https://uk.advfn.com/p.php?pid=staticchart&s=ASX%5EAGN&p=2&t=1

https://uk.advfn.com/p.php?pid=staticchart&s=ASX^AGN&p=6&t=1

 

[Dona Ferentes]

Argenica has successfully dosed five patients in its acute ischaemic stroke Phase 2 clinical trial, representing the first cohort of patients to be reviewed by the Data Safety Monitoring Board (DSMB), highlighting a promising early recruitment response to date. The patients, who presented to both the Royal Melbourne Hospital and Princess Alexandra Hospital emergency departments, were enrolled into the trial following meeting the inclusion criteria: a confirmed diagnosis of an acute ischaemic stoke caused by a large vessel occlusion (LVO) and were eligible for mechanical thrombectomy.

Now in TH for a capital raise